ALNY - Is This Unknown Growth Stock a Buy After Its Blast Off?
Alnylam Pharmaceuticals ' (NASDAQ: ALNY) stock went vertical in the past month -- up over 50% -- and there might be even more growth on the way. Sales of its top-earning medicines are booming, and breakthroughs in clinical trials have added to the enthusiasm.
But now could also be a dicey time to invest even though, on the surface, everything looks to be going swimmingly. Let's investigate why and think about when it might be a more favorable time to approach this stock.
Alnylam has a small handful of medicines on the market, led by its drugs Onpattro and Amvuttra, which are intended to treat peripheral neuropathy caused by hereditary transthyretin amyloidosis (ATTR), which is a rare but deadly and progressively worsening heart disease.
For further details see:
Is This Unknown Growth Stock a Buy After Its Blast Off?